Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Mitochondrial Dysfunction in the Response to Exercise in Patients With Advance Kidney Disease
NCT05422534Phase 3Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of coenzyme q10 in end stage renal disease (ESRD) (4 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Phosphocreatine recovery measured by 31 phosphorus magnetic resonance spectroscopy at 12 weeks. Started Jun 2023; status: recruiting.
02
Drugs
coenzyme q10
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05422534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422534.